RN1701 injection for relapsed or refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational drug called RN1701 for people whose B-cell lymphoma has come back or not responded to previous treatments. It aims to see if the drug can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma (such as large B-cell, follicular, or mantle cell) that has returned or not responded to prior therapy.
- You have at least one measurable tumor (at least 1.5 cm in lymph nodes or 1.0 cm elsewhere).
- Your cancer cells test positive for CD19 or CD20 markers.
- You are generally able to care for yourself (ECOG performance status 0-1).
- Your blood counts and organ function meet minimum levels (such as hemoglobin, platelets, kidney and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called RN1701 for people with certain types of B-cell lymphoma that have not responded to or have returned after previous treatments. The goal is to see if the drug can help control the cancer.
This trial tests a new treatment called RN1701 for patients with certain B-cell lymphomas that have not responded to or have returned after previous treatments. The treatment is given as an injection and aims to target and kill lymphoma cells that have CD19 or CD20 markers on them.
This trial tests a new treatment called RN1201 for blood cancers like multiple myeloma, certain leukemias, and lymphomas that have not improved with standard treatments or have returned. The treatment targets specific markers on cancer cells (CD19 and BCMA) and may offer a new option for patients who have run out of standard choices.
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
This study tests a new therapy called RS001 for people with B-cell lymphoma or B-cell leukemia that has not gotten better or has returned after treatment. It targets a marker called CD19 on cancer cells, and the goal is to see if it can help control the cancer.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.